Results 91 to 100 of about 13,843 (217)

Supplemental Materials: The Efficacy and Safety of Non-Biologic and Biologic Treatments in Palmoplantar Pustular Psoriasis & Palmoplantar Pustulosis: A Systematic Review and Network Meta-analysis

open access: yes
Supplemental Materials of The Efficacy and Safety of Non-Biologic and Biologic Treatments in Palmoplantar Pustular Psoriasis & Palmoplantar Pustulosis: A Systematic Review and Network Meta-analysis ResearchTHIS DATASET IS ARCHIVED AT DANS/EASY, BUT ...
AlShareef, K (via Mendeley Data)
core   +3 more sources

Pustulosis palmoplantar [PDF]

open access: yesRevista del Centro Dermatológico Pascua, 2021
Miguel Ángel Cardona Hernández   +4 more
openaire   +1 more source

Clinical Images: Successfully treated mandibular osteomyelitis by tumor necrosis factor inhibitor in SAPHO syndrome

open access: yes
Arthritis &Rheumatology, Volume 78, Issue 4, Page 993-994, April 2026.
Seiya Oba   +5 more
wiley   +1 more source

Erythrokeratodermia‐Cardiomyopathy Syndrome: Expanding the DSP Mutational Spectrum Beyond Proline Substitutions

open access: yesPediatric Dermatology, Volume 43, Issue 2, Page 444-447, March/April 2026.
ABSTRACT Erythrokeratodermia cardiomyopathy (EKC) syndrome is a rare autosomal dominant disorder characterized by generalized erythrokeratoderma and progressive dilated cardiomyopathy, caused by pathogenic variants in the SR6 domain of desmoplakin (DSP).
Sepideh Hamzehlou   +7 more
wiley   +1 more source

A genome-wide meta-analysis of palmoplantar pustulosis implicates Th2 responses and cigarette smoking in disease pathogenesis.

open access: yesmedRxiv
Background: Palmoplantar pustulosis (PPP) is an inflammatory skin disorder that mostly affects smokers and manifests with painful pustular eruptions on the palms and soles.
Ariana Hernández-Cordero   +25 more
semanticscholar   +1 more source

Table S2 - Supplemental material for Use of Janus Kinase Inhibitor Treatment for Palmoplantar Pustulosis: An Evidence-Based Review

open access: yes, 2023
Supplemental material, Table S2, for Use of Janus Kinase Inhibitor Treatment for Palmoplantar Pustulosis: An Evidence-Based Review by Siddhartha Sood, Abrahim Abduelmula, Khalad Maliyar, Jorge R.
Jorge R. Georgakopoulos (12281207)   +7 more
core   +1 more source

Palmoplantar pustulosis : an autoimmune disease precipitated by smoking

open access: yes, 2002
Ninety-five percent of patients with palmoplantar pustulosis are smokers at onset of the disease. The aim of this study was to determine whether these patients have serum antibodies to nicotinic acetylcholine receptors (nAChR ab) and if their sera induce
Lefvert, Ann-Kari   +4 more
core  

Table S3 - Supplemental material for Use of Janus Kinase Inhibitor Treatment for Palmoplantar Pustulosis: An Evidence-Based Review

open access: yes, 2023
Supplemental material, Table S3, for Use of Janus Kinase Inhibitor Treatment for Palmoplantar Pustulosis: An Evidence-Based Review by Siddhartha Sood, Abrahim Abduelmula, Khalad Maliyar, Jorge R.
Jorge R. Georgakopoulos (12281207)   +7 more
core   +1 more source

Metabolic profiling of psoriasis vulgaris and palmoplantar pustulosis. [PDF]

open access: yesExp Dermatol
Psoriasis is a chronic inflammatory skin disorder with various subtypes, including psoriasis vulgaris (PV) and palmoplantar pustulosis (PPP). Metabolomics studies have provided insights into psoriasis pathogenesis.
Lee Y   +5 more
europepmc   +2 more sources

Supplemental Material - Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry

open access: yes, 2022
Supplemental Material for Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry by Mark G. Lebwohl, MD, Rose Anne Medeiros, PhD, Rachel H. Mackey, PhD, Wendell C. Valdecantos,
Rose Anne Medeiros (14305940)   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy